(19)
(11) EP 2 968 398 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
19.06.2019 Bulletin 2019/25

(45) Mention of the grant of the patent:
17.04.2019 Bulletin 2019/16

(21) Application number: 14776071.4

(22) Date of filing: 12.03.2014
(51) International Patent Classification (IPC): 
A61K 31/715(2006.01)
C08G 63/48(2006.01)
 C12Q 1/00(2006.01)
A61P 35/00(2006.01)
(86) International application number:
PCT/US2014/024323
(87) International publication number:
WO 2014/159592 (02.10.2014 Gazette 2014/40)

(54)

MODIFIED HYALURONAN AND USES THEREOF IN CANCER TREATMENT

MODIFIZIERTES HYALURONAN UND VERWENDUNGEN DAVON BEI DER KREBSBEHANDLUNG

HYALURONANE MODIFIÉ ET SES UTILISATIONS DANS LE TRAITEMENT DU CANCER

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 14.03.2013 US 201313826952

(43) Date of publication of application:
20.01.2016 Bulletin 2016/03

(73) Proprietor: National Cheng Kung University
Tainan City 701 (TW)

(72) Inventors:
  • CHANG, Nan-Shan
    Owega, NY 13827 (US)
  • SU, Wan-Pei
    Nantou 558 (TW)

(74) Representative: Dehns 
St. Brides House 10 Salisbury Square
London EC4Y 8JD
London EC4Y 8JD (GB)


(56) References cited: : 
US-A- 5 902 795
US-A1- 2007 202 491
 US-A1- 2005 281 880
   
  • WANG FULI ET AL: "HYAL1 and HYAL2 Inhibit Tumour Growth In Vivo but Not In Vitro", PLOS ONE, vol. 3, no. 8, August 2008 (2008-08), XP002759604, ISSN: 1932-6203
  • ALANIZ L ET AL: "Low molecular weight hyaluronan inhibits colorectal carcinoma growth by decreasing tumor cell proliferation and stimulating immune response", CANCER LETTERS, NEW YORK, NY, US, vol. 278, no. 1, 8 June 2009 (2009-06-08), pages 9-16, XP026065468, ISSN: 0304-3835, DOI: 10.1016/J.CANLET.2008.12.029 [retrieved on 2009-01-29]
  • KUBO K ET AL: "DEPOLYMERIZATION OF HYALURONAN BY SONICATION", GLYCOCONJUGATE JOURNAL, CHAPMAN & HALL, BOSTON, vol. 10, no. 6, 1 December 1993 (1993-12-01), pages 435-439, XP000646443, ISSN: 0282-0080, DOI: 10.1007/BF00737963
  • LIU DACAI ET AL: "Expression of hyaluronidase by tumor cells induces angiogenesis in vivo", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 93, no. 15, 1996, pages 7832-7837, XP002759605, ISSN: 0027-8424
  • RODGERS LAUREL S ET AL: "Depolymerized hyaluronan induces vascular endothelial growth factor, a negative regulator of developmental epithelial-to-mesenchymal transformation.", CIRCULATION RESEARCH 15 SEP 2006, vol. 99, no. 6, 15 September 2006 (2006-09-15), pages 583-589, XP002759606, ISSN: 1524-4571
  • OSSIPOV, DA.: 'Nanostructured Hyaluronic Acid-Based Materials For Active Delivery To Cancer' EXPERT OPINION: DRUG DELIVERY vol. 7, no. 6, 01 June 2010, pages 681 - 703, XP008150189 DOI: 10.1517/17425241003730399
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).